Aptamers are a new class of molecules with a great potential to rival monoclonal antibodies in therapeutic, diagnostic, analytical as well as basic research applications. Described just over two decades ago, there has been an ever growing interest in these molecules as evidenced by the considerable increase in the number of related publications. Furthermore, the field of aptamer technology received a great boost in 2004 after the first FDA approved drug, Macugen, to treat age related macular degeneration, and later the development of the first aptamer based diagnostic platform for the analysis of mycotoxins in grain. In subsequent years there has been an outstanding growth in the Aptamer based companies and the range of developed products.
This symposium is one of the first international meetings at Oxford that will bring together the aptamer community from both academia and industry. This event would form the foundations for an annual gathering that would witness the aptamer technology coming of age.
We cordially invite you to the beautiful and historic city of Oxford to what we hope will be a memorable meeting.
Professor Said Ismail (Symposium Chair)
University of Jordan, Amman, Jordan
Academic and Research Institutes: Group and Lab Heads, Postdoctoral Scientists and Research Students
Biotech and Pharma Industry: Chief Scientists, Group Heads and Team Leaders, Senior and Junior Research Scientists